- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
- Profile
- Financials
Bicycle Therapeutics (BCYC)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 648.87 mm | 648.87 mm | 648.87 mm | 648.87 mm | 648.87 mm | 648.87 mm |
| Cash burn (monthly) | 24.38 mm | 20.21 mm | 21.85 mm | 24.17 mm | 23.72 mm | 19.98 mm |
| Cash used (since last report) | 84.93 mm | 70.42 mm | 76.13 mm | 84.21 mm | 82.66 mm | 69.61 mm |
| Cash remaining | 563.94 mm | 578.45 mm | 572.74 mm | 564.66 mm | 566.21 mm | 579.27 mm |
| Runway (months of cash) | 23.1 | 28.6 | 26.2 | 23.4 | 23.9 | 29.0 |
| 13F holders | Current |
|---|---|
| Total holders | 103 |
| Opened positions | 17 |
| Closed positions | 24 |
| Increased positions | 29 |
| Reduced positions | 35 |
| 13F shares | Current |
|---|---|
| Total value | 542.87 bn |
| Total shares | 49.93 mm |
| Total puts | 17.40 k |
| Total calls | 4.10 k |
| Total put/call ratio | 4.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Baker Bros. Advisors | 10.89 mm | $152.39 bn |
| Point72 Asset Management | 4.55 mm | $63.77 bn |
| Forbion Growth Opportunities Fund II Cooperatief U.A. | 3.45 mm | $50.68 mm |
| FCPM Iii Services B.V. | 3.45 mm | $48.33 bn |
| Westfield Capital Management | 2.61 mm | $36.54 bn |
| Armistice Capital | 2.20 mm | $30.74 bn |
| Siren, L.L.C. | 1.84 mm | $25.75 bn |
| T. Rowe Price | 1.59 mm | $22.19 mm |
| SVLSF V | 1.56 mm | $54.41 mm |
| GSK GSK | 1.53 mm | $39.40 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Jan 26 | Baker Bros. Advisors | American Depositary Shares | Grant | Acquire A | Yes | No | 0 | 19,000 | 0.00 | 10,018,674 |
| 2 Jan 26 | Baker Bros. Advisors | American Depositary Shares | Grant | Acquire A | Yes | No | 0 | 19,000 | 0.00 | 937,483 |
| 2 Jan 26 | Baker Bros. Advisors | Share Option [object Object] | Grant | Acquire A | Yes | No | 7.08 | 38,000 | 269.04 k | 38,000 |
| 2 Jan 26 | Baker Bros. Advisors | Share Option [object Object] | Grant | Acquire A | Yes | No | 7.08 | 38,000 | 269.04 k | 38,000 |
| 2 Jan 26 | Stephen H. Sands | Ordinary Shares | Grant | Acquire A | No | No | 0 | 9,500 | 0.00 | 26,893 |
| 2 Jan 26 | Stephen H. Sands | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 7.08 | 19,000 | 134.52 k | 19,000 |
| 2 Jan 26 | Alessandro Riva | Ordinary Shares | Grant | Acquire A | No | No | 0 | 7,380 | 0.00 | 19,880 |
| 2 Jan 26 | Alessandro Riva | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 7.08 | 14,761 | 104.51 k | 14,761 |
| 2 Jan 26 | Dansey Roger D | Ordinary Shares | Grant | Acquire A | No | No | 0 | 3,032 | 0.00 | 15,532 |
| 2 Jan 26 | Dansey Roger D | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 7.08 | 6,065 | 42.94 k | 6,065 |